Selexis CHO Cells in Suspension-1


Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein, because we have the ability to understand and modify our cells to address productivity and expression challenges.


A glimpse to the highlights of our ribbon-cutting opening event of our new colocalized Selexis and KBI CDMO facility in Geneva

July 2022

We recently held a ribbon-cutting at our state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.Together, Selexis and KBI Biopharma are globally known for tackling some of the most challenging biologics projects.

Keywords: #opening #Geneva#mammalian#endtoend#onestopshop

One Premier Location For Cell Line Development, Process Development And Manufacturing. Built For End-To-End Services, And Globally Known For Tackling Some Of The Most Challenging Biologics Projects

July 2022

Experience the power of KBI and Selexis in Geneva, with best-in-class cell line development, process development, and manufacturing together under one roof. Our Geneva premier Location For Cell Line Development, Process Development And Manufacturing. Built For End-To-End Services. Our fully integrated development platform has supported more than 60 clinical development programs with a seamless approach that optimizes the client experience. Explore our Geneva location for yourself in our new facility tour video.

Keywords: #Geneva#mammalian#endtoend#onestopshop#labtour#CDMO

Join our virtual lab tour at our Geneva CLD facility

November 2022

For over 20 years, Selexis' cutting-edge laboratories and technical experts have provided high quality services developing the best cell lines to global partners, from small biotech companies to some of the world’s largest and most innovative pharmaceutical companies. Discover the inside of new our state-of-the-art laboratory located Geneva, Switzerland, to see why innovation and quality are Selexis' main drivers.

Keywords: #Geneva#mammalian#CLD#labtour

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland

July 2022

KBI Biopharma and Selexis, both JSR Life Sciences companies, announce that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.

Keywords: #Geneva#mammalian#endtoend#onestopshop#CDMO


Maximize your biotherapeutic development success rate

July 2022

Meet Elodie Pothin, PhD, our Business Development Manager to learn to what extent Selexis can help you maximizing your biotherapeutic development success rate.
Get a glint of Selexis cell line development: speed, high titer, minimal risks, regulatory compliant and stable. Experience outstanding one-stop-shop from gene to GMP with Selexis and KBI working together.

What is it like when the cell line development leader join forces with best analytics CDMO?

July 2022

Meet Roland Hecht, PhD, our Senior Vice President Business Development Europe and Asia to witness what it is like when cell line development leader Selexis joins forces with KBI, the CDMO with the best analytical platform worldwide.
When the bests in their fields meets and join forces, expect limits to be pushed back. With their brand new facility in Geneva, under one roof, Selexis and KBI are working together to develop your novel biotherapeutics within agressive timelines, from gene transfection to cGMP production. Rocket speed without compromise on quality: that's the power of together. And it's all for your benefit.

Excitement at work

July 2022

Meet Maria-Pilar Giménez Muñoz, our Marketing Associate Director to hear what it feels like to work in a purpose-driven company such as Selexis.

Why is Selexis a Great Place to Work?

July 2022

Meet Alberto Garotti, our Senior Vice President - Site Head of Geneva to hear why Selexis is a Great Place to Work.
Learn about Selexis' happy culture of commited team-work and flexible management.

Reach high titers with the right format in difficult-to-express protein production

July 2022

Meet Séverine Fagète, PhD, our Cell Line Services Vice President to see how Selexis achives best-in-class difficult-to-express titer in stable cell lines.
Learn more about bispecific antibody molar ratio, overcoming secretion bottleneck and auxiliary protein expression. Hear about aggregation and folding problem-solving.

Keywords: #celllinedevelopment #CLD#mammalian#SUREtechnology

Your project is unique and so do we treat you

July 2022

Meet Sonja Delalu, PhD, our Business Development and Licensing Director to see how your new biotherapeutic project will be valued at Selexis.

Join a purpose-oriented company

July 2022

Meet Thomas Clames, our Business Development Finance Controller to hear what it feels like to work in a purpose-driven company such as Selexis.

Your biotherapeutic program is the only one in the hands of an absolute expert in the field - Experience the feeling

July 2022

Meet Regine Brokamp, our Chief Operating Officier to hear how your new biotherapeutic program will be pampered at Selexis.
With Selexis, experience an absolute expert's deep-understanding of your program. Feel that your are valued no matter where you come from. Rest your mind and relly on our experience. Know that your timelines will be brought up-to-speed without compromising on quality. Work with a team that listens to your needs and goes the extra mile for you.